Research chemicalStimulantResearch chemicalPiperazine
MBZP
Also known as MBZP · 1-Methyl-4-benzylpiperazine
MBZP (1-methyl-4-benzylpiperazine) is a benzylpiperazine analogue used recreationally as a mild stimulant, often as a party pill component. It is weaker than BZP with sparse human data.
01 Overview
MBZP (1-methyl-4-benzylpiperazine) is a close analogue of BZP that appeared in party pill blends. It is generally described as a milder stimulant than BZP.
Human pharmacological study is minimal, and most information derives from user reports and its structural relationship to BZP. It shares the broad stimulant and adverse-effect character of the benzylpiperazine class.
02 Mechanism
Presumed dopamine and noradrenaline releaser and reuptake inhibitor similar to BZP, with lower potency.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light | 50–100 mg | Oral | Anecdotal light range. |
| Common | 100–200 mg | Oral | Anecdotal; reported as milder than BZP. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Mild stimulationEnergy and alertness reported as weaker than BZP. | mild | Anecdotal | |
| Mild mood liftModest euphoria at common doses. | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Anxiety and restlessnessAnxiety and jitteriness reported, consistent with the benzylpiperazine class. | Moderate | Common | Anecdotal | |
| InsomniaDifficulty sleeping following use. | Moderate | Common | Anecdotal |
06 Legal status
NZ
Class C controlled drug
Scheduled with related piperazines. · as of Jan 2026
United States
Analogue exposure possible
Not explicitly scheduled federally; may fall under analogue provisions. · as of Jan 2026
07 References
Benzylpiperazine analogues in party pillsPubMed
Piperazine derivatives drug profileEUDA (European Union Drugs Agency)
08 Discussion0 comments
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.